MacroPore Biosurgery takes a multifaceted approach to regenerative cell therapy in which technologies involving cells, devices, and drugs in regenerative cell therapy will be combined and used on clinical applications, including cardiovascular tissue repair, spinal disc regeneration, bone regeneration, wound healing, and cosmetic and reconstructive surgery. MacroPore has concentrated on research, development, and commercialization of regenerative medicine technologies, and has bioresorbable and regenerative cell technologies that allow the company to target the large spine and orthopedic bone repair and cardiovascular disease medical markets. MacroPore wants to deliver an autologous (taken from a person's own tissues, cells, or DNA) point of care cell therapy system for regeneration and repair of damaged tissues, says Marc H. Hedrick, M.D., president of MacroPore. Currently, MacroPore is the only active company that is developing adipose-derived stem cell applications, says Dr. Hedrick. MacroPore, which is a combination products company that uses device-based technology to enable a biotechnology-based clinical solution, is developing drugs to elute stem cells, disposable devices for use in treating the heart, and manufacturing devices for cell therapy solutions. Since Dr. Hedrick reported the presence of adult stem cells in adipose tissue in 2001, more research laboratories are using adipose as a cell source, but the primary difference among various approaches is the sources of the cell, which are known to include bone marrow, peripheral blood, skeletal muscle, and adipose tissue. Among topics covered are adipose-derived cell therapy; applications; and the future of regenerative healing, including MacroPore's active preclinical program for using stem cells in bone repair, spinal disc repair, soft tissue reconstruction, wound healing, and peripheral vascular disease.